Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

431 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dasatinib in relapsed or plateau-phase multiple myeloma.
Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Wildes TM, et al. Among authors: vij r. Leuk Lymphoma. 2009 Jan;50(1):137-40. doi: 10.1080/10428190802563363. Leuk Lymphoma. 2009. PMID: 19152174 Clinical Trial. No abstract available.
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. Vij R, et al. Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30. Br J Haematol. 2012. PMID: 22845873 Free PMC article. Clinical Trial.
New Treatment Approaches for Older Adults with Multiple Myeloma.
Wildes TM, Vij R, Petersdorf SH, Medeiros BC, Hurria A. Wildes TM, et al. Among authors: vij r. J Geriatr Oncol. 2012 Jul;3(3):279-290. doi: 10.1016/j.jgo.2012.02.001. Epub 2012 Feb 28. J Geriatr Oncol. 2012. PMID: 23024730 Free PMC article.
Carfilzomib in multiple myeloma.
Vij R. Vij R. Clin Adv Hematol Oncol. 2012 Sep;10(9):591-3. Clin Adv Hematol Oncol. 2012. PMID: 23073124 No abstract available.
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R. Wang TF, et al. Among authors: vij r. Leuk Lymphoma. 2014 Feb;55(2):337-41. doi: 10.3109/10428194.2013.803547. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23662990 Free PMC article.
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Jakubowiak AJ, et al. Among authors: vij r. Leukemia. 2013 Dec;27(12):2351-6. doi: 10.1038/leu.2013.152. Epub 2013 May 14. Leukemia. 2013. PMID: 23670297 Free PMC article. Clinical Trial.
Influence of body mass index on survival in veterans with multiple myeloma.
Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, Dipersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR. Beason TS, et al. Among authors: vij r. Oncologist. 2013;18(10):1074-9. doi: 10.1634/theoncologist.2013-0015. Epub 2013 Sep 18. Oncologist. 2013. PMID: 24048366 Free PMC article.
431 results